

TSCA HEALTH & SAFETY STUDY COVER SHEET - revised 6/25/96

TSCA CBI STATUS:

**CHECK IF THIS PAGE CONTAINS CONFIDENTIAL BUSINESS INFORMATION (CBI)**

Clearly mark the confidential information with bracketing and check the box in the appropriate section ( Contains CBI).  
Submit a sanitized cover sheet with CBI deleted. Mark the sanitized copy, "Public Display Copy" in the heading.

<b>1.0 SUBMISSION TYPE</b> <input type="checkbox"/> Contains CBI <input type="checkbox"/> 8(d) <input checked="" type="checkbox"/> 8(e) <input type="checkbox"/> FYI <input type="checkbox"/> 4 <input type="checkbox"/> OTHER: Specify <u>BEHQ - 0299-14384</u> <input checked="" type="checkbox"/> Initial Submission <input type="checkbox"/> Follow-up Submission <input type="checkbox"/> Final Report Submission Previous EPA Submission Number or Title if update or follow-up: _____ Docket Number, if any: # _____ <input type="checkbox"/> continuation sheet attached		
<b>2.1 SUMMARY/ABSTRACT ATTACHED</b> (may be required for 8(e): optional for §4, 8(d) & FYI)  <input checked="" type="checkbox"/> YES <input type="checkbox"/> NO	<b>2.2 SUBMITTER TRACKING NUMBER OR INTERNAL ID</b>  99-127	<b>2.3 FOR EPA USE ONLY</b>  FEB 22 PM 3:36
<b>3.0 CHEMICAL/TEST SUBSTANCE IDENTITY</b> <input type="checkbox"/> Contains CBI <i>Reported Chemical Name (specify nomenclature if other than CAS name):</i> CAS# <u>1563-38-8</u> Purity <u>UNK</u> % <b>7-Benzofuranol, 2,3-dihydro-2,2-dimethyl-</b> <input type="checkbox"/> Single Ingredient <input checked="" type="checkbox"/> Commercial/Tech Grade <input type="checkbox"/> Mixture    Trade Name: <u>7-Hydroxy</u> Common Name: <u>7-Hydroxy</u> CAS Number    NAME    % WEIGHT Other chemical(s) present in tested mixture _____ <input type="checkbox"/> continuation sheet attached		
<b>4.0 REPORT/STUDY TITLE</b> <input type="checkbox"/> Contains CBI  Pilot Oral Teratology Study in Rats with 7-Hydroxy		 BEHQ-99-14384
<b>5.1 STUDY/TSCATS INDEXING TERMS</b> [CHECK ONE] HEALTH EFFECTS (HE): <input checked="" type="checkbox"/> ENVIRONMENTAL EFFECTS (EE): _____    ENVIRONMENTAL FATE (EF): _____		
<b>5.2 STUDY/TSCATS INDEXING TERMS</b> (see instructions for 4 digit codes) STUDY    SUBJECT    ROUTE OF    VEHICLE OF TYPE: <u>TERA</u> ORGANISM (HE, EE only): <u>RATS</u> EXPOSURE (HE only): <u>GAVG</u> EXPOSURE (HE only): _____ Other: _____    Other: _____    Other: <u>GELATIN CAPSULE</u>		
<b>6.0 REPORT/STUDY INFORMATION</b> <input type="checkbox"/> Contains CBI <input checked="" type="checkbox"/> Study is GLP Laboratory <u>FMC Toxicology Laboratory</u> Report/Study Date <u>on-going</u> Source of Data/Study Sponsor (if different than submitter) _____    Number of pages _____ <input type="checkbox"/> continuation sheet attached		
<b>7.0 SUBMITTER INFORMATION</b> <input type="checkbox"/> Contains CBI Submitter: <u>Linda M. Clark</u> Title: <u>Manager, Product Reg. Affairs</u> Phone: <u>(215) 299-6133</u> Company Name: <u>FMC Corporation</u> Company Address: <u>1735 Market Street</u> <u>Philadelphia, PA 19103</u> Submitter Address (if different): _____ Technical Contact: <u>Christine Freeman</u> Phone: <u>(609) 951-3731</u> <input type="checkbox"/> continuation sheet attached		
<b>8.0 ADDITIONAL/OPTIONAL STUDY COMMENTS</b> <input type="checkbox"/> Contains CBI <input type="checkbox"/> continuation sheet attached		

99 MAR 31 AM 9:38

RECEIVED  
OPT NCIC



RECEIVED  
OPT NCIC

Submitter Signature: Linda M. Clark

Date: 2/18/99

17793

CONTAINS NO CBI

9.0 CONTINUATION SHEET

TSCA CBI STATUS:

**CHECK IF THIS PAGE CONTAINS CONFIDENTIAL BUSINESS INFORMATION (CBI)**

Clearly mark the confidential information with bracketing and check the box in the appropriate section ( Contains CBI).  
Submit a sanitized cover sheet with CBI deleted. Mark the sanitized copy, "Public Display Copy" in the heading.

Submitter Tracking Number/Internal ID

99-127

CONTINUED FROM COVER SHEET SECTION # 2.1

*Contains CBI*

**Eight pregnant rats/group received the test material undiluted (in gelatin capsule) via oral gavage at doses of 0, 100, 500 or 1000 mg/kg/day daily on gestation days 6 through 19.**

**The study is deemed reportable due to the decreased fetal body weights noted at 500 and 1000 mg/kg/day. Fetal body weights were reduced, although not significantly, at 100 mg/kg/day when compared to the controls.**

**Other effects noted during the study included maternal clinical signs, decreased maternal body weights and decreased maternal food consumption noted in all treated groups. Three dams receiving 1000 mg/kg/day were sacrificed due to a moribund condition on gestation days 7-8.**

CONTAINS CBI